The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 166:935-a-936, August 2009
doi: 10.1176/appi.ajp.2009.09050639
© 2009 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Google Scholar
* Articles by MOORE, S.
* Articles by COONEY, J.
PubMed
* Articles by MOORE, S.
* Articles by COONEY, J.
Related Collections
* Antidepressants

Letter to the Editor

Potential Limitations in Generalizing Findings From the TORDIA Study

SUSAN MOORE, M.D., and JOHN COONEY, M.D.
Dublin, Ireland

To the Editor: In the April 2009 issue of the Journal, David A. Brent, M.D., et al. (1) examined predictors of suicidal adverse events in the treatment of selective serotonin reuptake inhibitor (SSRI) resistant depression in adolescents. The authors found that adjunctive use of benzodiazepines in a small patient group (N=10 [3% of the total sample]) was associated with a higher rate of both suicidal and non-suicidal self-injury. They concluded that the disinhibitory effects of benzodiazepines may lead to increased risk-taking behavior. This finding was reiterated in an accompanying editorial (2).

We suggest that this finding in such a small subgroup more likely represents a selection bias. Patients with comorbid anxiety disorders who have a higher risk of suicidal behaviors (3) are more likely to require adjunctive pharmacological treatment. Benzodiazepines may also have been prescribed for high levels of distress or agitation in this subgroup, which would also lead to an increase in self-harming behaviors. Given the small sample size and lack of information about comorbid diagnoses, the authors’ conclusion cannot be generalized to the population as a whole.

Footnotes

Dr. Cooney has served on the speaker’s bureau for Eli Lilly, GlaxoSmithKline, and Pfizer; and he has served on an advisory panel for Servier. Dr. Moore reports no competing interests.

This letter (doi: 10.1176/appi.ajp.2009.09050639) was accepted for publication in June 2009.

References

  1. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, DeBar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB: Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2009; 166:418–426[Abstract/Free Full Text]
  2. Weissman MM: Teenaged, depressed, and treatment resistant: What predicts self-harm? Am J Psychiatry 2009; 166:385–387[Free Full Text]
  3. Foley DL, Goldston DB, Costello EJ, Angold A: Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountain Study. Arch Gen Psychiatry 2006; 63:1017–1024[Abstract/Free Full Text]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Google Scholar
* Articles by MOORE, S.
* Articles by COONEY, J.
PubMed
* Articles by MOORE, S.
* Articles by COONEY, J.
Related Collections
* Antidepressants


Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org